JIYOUNG CHAE: Open Payments
NPI 1568845295 · WEST LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$903 in 47 payments from 15 companies in 2025. Trend: 2023 $677 · 2024 $856 · 2025 $903
Food & beverage: $903
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $194 |
| Neurocrine BioSciences, Inc. | 8 | $169 |
| Lilly USA, LLC | 7 | $123 |
| Eisai Inc. | 5 | $99 |
| Novo Nordisk Inc | 4 | $77 |
| PFIZER INC. | 3 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
Products named: REXULTI, INGREZZA, Leqembi, KISUNLA, Rybelsus, Kerendia, ELIQUIS, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
